{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:07:59Z","timestamp":1792804079942,"version":"4.5.0"},"reference-count":199,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00198-022-06631-4","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T13:03:04Z","timestamp":1670936584000},"page":"449-466","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Fracture risk and assessment in adults with cancer"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-5398","authenticated-orcid":false,"given":"Carrie","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1056-1691","authenticated-orcid":false,"given":"William D.","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"6631_CR1","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00198-011-1724-9","volume":"23","author":"M Reuss-Borst","year":"2012","unstructured":"Reuss-Borst M, Hartmann U, Scheede C, Wei\u00df J (2012) Prevalence of osteoporosis among cancer patients in Germany. Osteoporos Int 23:1437\u20131444","journal-title":"Osteoporos Int"},{"key":"6631_CR2","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s\u20136249s","journal-title":"Clin Cancer Res"},{"key":"6631_CR3","doi-asserted-by":"publisher","first-page":"e0532","DOI":"10.1097\/MD.0000000000010532","volume":"97","author":"GH Seo","year":"2018","unstructured":"Seo GH, Kang HY, Choe EK (2018) Osteoporosis and fracture after gastrectomy for stomach cancer. Med 97:e0532","journal-title":"Med"},{"key":"6631_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","volume":"18","author":"SS Faubion","year":"2015","unstructured":"Faubion SS, Kuhle CL, Shuster LT, Rocca WA (2015) Long-term health consequences of premature or early menopause and considerations for management. Climacteric 18:483\u2013491","journal-title":"Climacteric"},{"key":"6631_CR5","doi-asserted-by":"publisher","first-page":"20160885","DOI":"10.1259\/bjr.20160885","volume":"90","author":"L Bazire","year":"2017","unstructured":"Bazire L, Xu H, Foy J-P et al (2017) Pelvic insufficiency fracture (PIF) incidence in patients treated with intensity-modulated radiation therapy (IMRT) for gynaecological or anal cancer: single-institution experience and review of the literature. Br J Radiol 90:20160885","journal-title":"Br J Radiol"},{"key":"6631_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jgo.2014.10.003","volume":"6","author":"TM Wildes","year":"2015","unstructured":"Wildes TM, Dua P, Fowler SA et al (2015) Systematic review of falls in older adults with cancer. J Geriatr Oncol 6:70\u201383","journal-title":"J Geriatr Oncol"},{"key":"6631_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2105\/AJPH.82.3.395","volume":"82","author":"JE Dunn","year":"1992","unstructured":"Dunn JE, Rudberg MA, Furner SE, Cassel CK (1992) Mortality, disability, and falls in older persons: the role of underlying disease and disability. Am J Public Health 82:395\u2013400","journal-title":"Am J Public Health"},{"key":"6631_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jgo.2013.10.002","volume":"5","author":"PR Ward","year":"2014","unstructured":"Ward PR, Wong MD, Moore R, Naeim A (2014) Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: a retrospective cohort study. J Geriatr Oncol 5:57\u201364","journal-title":"J Geriatr Oncol"},{"key":"6631_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/rnj.0000000000000173","volume":"43","author":"G Campbell","year":"2018","unstructured":"Campbell G, Wolfe RA, Klem ML (2018) Risk Factors for Falls in Adult Cancer Survivors: An Integrative Review. Rehabil Nurs 43:201\u2013213","journal-title":"Rehabil Nurs"},{"key":"6631_CR10","unstructured":"Kocarnik JM, Compton K, Dean FE, et al (2021) Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol 8(3):420\u2013444."},{"key":"6631_CR11","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","volume":"17","author":"O Johnell","year":"2006","unstructured":"Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726\u20131733","journal-title":"Osteoporos Int"},{"key":"6631_CR12","unstructured":"Singh H, Al-Azazi S, Yan L, Lix L, Czaykowski P, Edwards B, Leslie WD (2017) Fracture Risk Among 122,205 Cancer Patients: A Population-Based Cohort Study from Manitoba, Canada. J Bone Miner Res 32 (Suppl 1). Available at https:\/\/www.asbmr.org\/meetings\/2017-abstracts. Accessed May 18, 2022"},{"key":"6631_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06542-4","author":"C Ye","year":"2022","unstructured":"Ye C, Leslie WD, Al-Azazi S et al (2022) Fractures and long-term mortality in cancer patients: a population-based cohort study. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-022-06542-4","journal-title":"Osteoporos Int"},{"key":"6631_CR14","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00198-021-06236-3","volume":"33","author":"C Ye","year":"2022","unstructured":"Ye C, Schousboe JT, Morin SN et al (2022) Time since prior fracture affects mortality at the time of clinical assessment: a registry-based cohort study. Osteoporos Int 33:1257\u20131264","journal-title":"Osteoporos Int"},{"key":"6631_CR15","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2105\/AJPH.87.3.398","volume":"87","author":"FD Wolinsky","year":"1997","unstructured":"Wolinsky FD, Fitzgerald JF, Stump TE (1997) The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study. Am J Public Health 87:398\u2013403","journal-title":"Am J Public Health"},{"key":"6631_CR16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","volume":"353","author":"JR Center","year":"1999","unstructured":"Center JR, Center JR, Nguyen TV et al (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. The Lancet 353:878\u2013882","journal-title":"The Lancet"},{"key":"6631_CR17","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nrendo.2014.125","volume":"10","author":"SE Sattui","year":"2014","unstructured":"Sattui SE, Saag KG (2014) Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol 10:592\u2013602","journal-title":"Nat Rev Endocrinol"},{"key":"6631_CR18","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/bjc.2016.314","volume":"115","author":"E Colzani","year":"2016","unstructured":"Colzani E, Clements M, Johansson ALV et al (2016) Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. Br J Cancer 115:1400\u20131407","journal-title":"Br J Cancer"},{"key":"6631_CR19","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/bju.13441","volume":"118","author":"ER Jefferies","year":"2016","unstructured":"Jefferies ER, Bahl A, Hounsome L et al (2016) Admissions to hospital due to fracture in England in patients with prostate cancer treated with androgen-deprivation therapy - do we have to worry about the hormones? BJU Int 118:416\u2013422","journal-title":"BJU Int"},{"key":"6631_CR20","doi-asserted-by":"crossref","unstructured":"Nikkel LE, Mahmood B, Lander S et al (2017) Hospitalizations for fracture in patients with metastatic disease: Primary source lesions in the United States. J Community Supportive Oncol 15:e14-e20.","DOI":"10.12788\/jcso.0385"},{"key":"6631_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s00198-020-05596-6","volume":"32","author":"WD Leslie","year":"2021","unstructured":"Leslie WD, Edwards B, Al-Azazi S et al (2021) Cancer patients with fractures are rarely assessed or treated for osteoporosis: a population-based study. Osteoporos Int 32:333\u2013341","journal-title":"Osteoporos Int"},{"key":"6631_CR22","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s00198-017-4218-6","volume":"28","author":"OL Tseng","year":"2017","unstructured":"Tseng OL, Dawes MG, Spinelli JJ et al (2017) Utilization of bone mineral density testing among breast cancer survivors in British Columbia, Canada. Osteoporos Int 28:3439\u20133449","journal-title":"Osteoporos Int"},{"key":"6631_CR23","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00198-018-4758-4","volume":"30","author":"R Hamood","year":"2019","unstructured":"Hamood R, Hamood H, Merhasin I, Keinan-Boker L (2019) Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations. Osteoporos Int 30:187\u2013200","journal-title":"Osteoporos Int"},{"key":"6631_CR24","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/jbmr.4250","volume":"36","author":"H Lu","year":"2021","unstructured":"Lu H, Lei X, Zhao H et al (2021) Bone Mineral Density at the Time of Initiating Aromatase Inhibitor Therapy Is Associated With Decreased Fractures in Women With Breast Cancer. J Bone Miner Res 36:861\u2013871","journal-title":"J Bone Miner Res"},{"key":"6631_CR25","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00198-014-2997-6","volume":"26","author":"AN Damji","year":"2015","unstructured":"Damji AN, Bies K, Alibhai SMH, Jones JM (2015) Bone health management in men undergoing ADT: examining enablers and barriers to care. Osteoporos Int 26:951\u2013959","journal-title":"Osteoporos Int"},{"key":"6631_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.4103\/0970-1591.105750","volume":"28","author":"A Mandhani","year":"2012","unstructured":"Mandhani A, Chipde S, Srivastava A et al (2012) Bone densitometric assessment and management of fracture risk in Indian men of prostate cancer on androgen deprivation therapy: Does practice pattern match the guidelines? Indian J Urol 28:399","journal-title":"Indian J Urol"},{"key":"6631_CR27","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1100\/tsw.2007.202","volume":"7","author":"WS Ngu","year":"2007","unstructured":"Ngu WS, Byrne DJ (2007) The Practice of Scottish Urologists in the Assessment and Management of Fracture Risk in the Ageing Male being Treated for Prostate Cancer. Sci World J 7:1590\u20131595","journal-title":"Sci World J"},{"key":"6631_CR28","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.urology.2012.11.066","volume":"81","author":"A-A Zhumkhawala","year":"2013","unstructured":"Zhumkhawala A-A, Gleason JM, Cheetham TC et al (2013) Osteoporosis management program decreases incidence of hip fracture in patients with prostate cancer receiving androgen deprivation therapy. Urol 81:1010\u20131015","journal-title":"Urol"},{"key":"6631_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11764-009-0083-4","volume":"3","author":"CJ Stava","year":"2009","unstructured":"Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R (2009) Skeletal sequelae of cancer and cancer treatment. J Cancer Surviv 3:75\u201388","journal-title":"J Cancer Surviv"},{"key":"6631_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(06)70694-5","volume":"7","author":"I Herr","year":"2006","unstructured":"Herr I, Pfitzenmaier J (2006) Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol 7:425\u2013430","journal-title":"Lancet Oncol"},{"key":"6631_CR31","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/S0140-6736(02)11922-2","volume":"360","author":"HP Rutz","year":"2002","unstructured":"Rutz HP (2002) Effects of corticosteroid use on treatment of solid tumours. Lancet 360:1969\u20131970","journal-title":"Lancet"},{"key":"6631_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6:38","journal-title":"Nat Rev Dis Primers"},{"key":"6631_CR33","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jbspin.2003.02.001","volume":"71","author":"E Fontanges","year":"2004","unstructured":"Fontanges E, Fontana A, Delmas P (2004) Osteoporosis and breast cancer. Joint Bone Spine 71:102\u2013110","journal-title":"Joint Bone Spine"},{"key":"6631_CR34","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/jbmr.1556","volume":"27","author":"LJ Melton","year":"2012","unstructured":"Melton LJ, Joseph Melton L, Hartmann LC et al (2012) Fracture risk in women with breast cancer: A population-based study. J Bone Miner Res 27:1196\u20131205","journal-title":"J Bone Miner Res"},{"key":"6631_CR35","doi-asserted-by":"publisher","first-page":"787","DOI":"10.4184\/asj.2016.10.4.787","volume":"10","author":"K-C An","year":"2016","unstructured":"An K-C (2016) Selective Estrogen Receptor Modulators. Asian Spine J 10:787\u2013791","journal-title":"Asian Spine J"},{"key":"6631_CR36","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3389\/fonc.2020.00366","volume":"10","author":"J Lee","year":"2020","unstructured":"Lee J, Alqudaihi HM, Kang MS et al (2020) Effect of Tamoxifen on the Risk of Osteoporosis and Osteoporotic Fracture in Younger Breast Cancer Survivors: A Nationwide Study. Front Oncol 10:366","journal-title":"Front Oncol"},{"key":"6631_CR37","doi-asserted-by":"publisher","first-page":"5227","DOI":"10.1200\/JCO.2007.15.7123","volume":"26","author":"AL Cooke","year":"2008","unstructured":"Cooke AL, Metge C, Lix L et al (2008) Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol 26:5227\u20135232","journal-title":"J Clin Oncol"},{"key":"6631_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","volume":"69","author":"P Hadji","year":"2009","unstructured":"Hadji P (2009) Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 69:73\u201382","journal-title":"Crit Rev Oncol Hematol"},{"key":"6631_CR39","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00432-010-0964-y","volume":"137","author":"P Hadji","year":"2011","unstructured":"Hadji P, Asmar L, van Nes JGH et al (2011) The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies. J Cancer Res Clin Oncol 137:1015\u20131025","journal-title":"J Cancer Res Clin Oncol"},{"key":"6631_CR40","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00223-015-0046-x","volume":"97","author":"SJ Lee","year":"2015","unstructured":"Lee SJ, Kim KM, Brown JK et al (2015) Negative Impact of Aromatase Inhibitors on Proximal Femoral Bone Mass and Geometry in Postmenopausal Women with Breast Cancer. Calcif Tissue Int 97:551\u2013559","journal-title":"Calcif Tissue Int"},{"key":"6631_CR41","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/annonc\/mdn762","volume":"20","author":"P Hadji","year":"2009","unstructured":"Hadji P, Ziller M, Kieback DG et al (2009) Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol 20:1203\u20131209","journal-title":"Ann Oncol"},{"key":"6631_CR42","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00432-014-1726-z","volume":"140","author":"I Kyvernitakis","year":"2014","unstructured":"Kyvernitakis I, Rachner TD, Urbschat A et al (2014) Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. J Cancer Res Clin Oncol 140:1671\u20131680","journal-title":"J Cancer Res Clin Oncol"},{"key":"6631_CR43","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0140-6736(05)67036-5","volume":"366","author":"A Howell","year":"2005","unstructured":"Howell A (2005) Adjuvant aromatase inhibitors for breast cancer. Lancet 366:431\u2013433","journal-title":"Lancet"},{"key":"6631_CR44","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","volume":"8","author":"RE Coleman","year":"2007","unstructured":"Coleman RE, Banks LM, Girgis SI et al (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8:119\u2013127","journal-title":"Lancet Oncol"},{"key":"6631_CR45","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss PE, Ingle JN, Martino S et al (2005) Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. JNCI: J Natl Cancer Inst 97:1262\u20131271","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"6631_CR46","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bone.2018.09.010","volume":"117","author":"M Pineda-Moncus\u00ed","year":"2018","unstructured":"Pineda-Moncus\u00ed M, Servitja S, Casamayor G et al (2018) Bone health evaluation one year after aromatase inhibitors completion. Bone 117:54\u201359","journal-title":"Bone"},{"key":"6631_CR47","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1200\/jco.2005.23.16_suppl.531","volume":"23","author":"PE Lonning","year":"2005","unstructured":"Lonning PE, Geisler J, Krag LE et al (2005) Changes in bone metabolism after 2 years\u2019 treatment with exemestane (E) in postmenopausal women with early breast cancer (EBC) at low risk: Follow-up (FU) results of a randomized placebo-controlled study. J Clin Oncol 23:531\u2013531","journal-title":"J Clin Oncol"},{"key":"6631_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","volume":"9","author":"JF Forbes","year":"2008","unstructured":"Forbes JF, Cuzick J, Buzdar A et al (2008) Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists\u2019 Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45\u201353","journal-title":"Lancet Oncol"},{"key":"6631_CR49","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","volume":"11","author":"J Cuzick","year":"2010","unstructured":"Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135\u20131141","journal-title":"Lancet Oncol"},{"key":"6631_CR50","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","volume":"20","author":"M Rabaglio","year":"2009","unstructured":"Rabaglio M, Sun Z, Price KN et al (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1\u201398 trial. Ann Oncol 20:1489\u20131498","journal-title":"Ann Oncol"},{"key":"6631_CR51","doi-asserted-by":"crossref","unstructured":"Lee Y-K, Lee E-G, Kim HY, et al (2020) Osteoporotic Fractures of the Spine, Hip, and Other Locations after Adjuvant Endocrine Therapy with Aromatase Inhibitors in Breast Cancer Patients: a Meta-analysis. J Korean Med Sci 35","DOI":"10.3346\/jkms.2020.35.e403"},{"key":"6631_CR52","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10147-012-0512-7","volume":"19","author":"H Takeuchi","year":"2014","unstructured":"Takeuchi H, Takei H, Futsuhara K et al (2014) A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06). Int J Clin Oncol 19:68\u201373","journal-title":"Int J Clin Oncol"},{"key":"6631_CR53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10549-015-3661-3","volume":"155","author":"N Schmidt","year":"2016","unstructured":"Schmidt N, Jacob L, Coleman R et al (2016) The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom. Breast Cancer Res Treat 155:151\u2013157","journal-title":"Breast Cancer Res Treat"},{"key":"6631_CR54","doi-asserted-by":"publisher","first-page":"e0130725","DOI":"10.1371\/journal.pone.0130725","volume":"10","author":"C-H Chang","year":"2015","unstructured":"Chang C-H, Chen S-J, Liu C-Y (2015) Fracture Risk and Adjuvant Therapies in Young Breast Cancer Patients: A Population-Based Study. PLOS One 10:e0130725","journal-title":"PLOS ONE"},{"key":"6631_CR55","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s11764-017-0666-4","volume":"12","author":"JM Neuner","year":"2018","unstructured":"Neuner JM, Shi Y, Kong AL et al (2018) Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy. J Cancer Surviv 12:268\u2013275","journal-title":"J Cancer Surviv"},{"key":"6631_CR56","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/jbmr.3726","volume":"34","author":"WD Leslie","year":"2019","unstructured":"Leslie WD, Morin SN, Lix LM et al (2019) Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. J Bone Miner Res 34:1428\u20131435","journal-title":"J Bone Miner Res"},{"key":"6631_CR57","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/epirev\/mxt010","volume":"36","author":"MF Munsell","year":"2014","unstructured":"Munsell MF, Sprague BL, Berry DA et al (2014) Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev 36:114\u2013136","journal-title":"Epidemiol Rev"},{"key":"6631_CR58","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jbmr.2017","volume":"29","author":"H Johansson","year":"2014","unstructured":"Johansson H, Kanis JA, Od\u00e9n A et al (2014) A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res 29:223\u2013233","journal-title":"J Bone Miner Res"},{"key":"6631_CR59","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/cncr.23674","volume":"113","author":"Z Chen","year":"2008","unstructured":"Chen Z, Arendell L, Aickin M et al (2008) Hip bone density predicts breast cancer risk independently of Gail score: results from the Women\u2019s Health Initiative. Cancer 113:907\u2013915","journal-title":"Cancer"},{"key":"6631_CR60","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJM199702273360903","volume":"336","author":"Y Zhang","year":"1997","unstructured":"Zhang Y, Kiel DP, Kreger BE et al (1997) Bone Mass and the Risk of Breast Cancer among Postmenopausal Women. N Engl J Med 336:611\u2013617","journal-title":"N Engl J Med"},{"key":"6631_CR61","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s10549-010-1138-y","volume":"126","author":"D Grenier","year":"2011","unstructured":"Grenier D, Cooke AL, Lix L et al (2011) Bone mineral density and risk of postmenopausal breast cancer. Breast Cancer Res Treat 126:679\u2013686","journal-title":"Breast Cancer Res Treat"},{"key":"6631_CR62","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3109\/13697137.2011.557754","volume":"14","author":"M Kalder","year":"2011","unstructured":"Kalder M, J\u00e4ger C, Seker-Pektas B et al (2011) Breast cancer and bone mineral density: the Marburg Breast Cancer and Osteoporosis Trial (MABOT II). Climacteric 14:352\u2013361","journal-title":"Climacteric"},{"key":"6631_CR63","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(18)30047-0","volume":"6","author":"TD Rachner","year":"2018","unstructured":"Rachner TD, Coleman R, Hadji P, Hofbauer LC (2018) Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol 6:901\u2013910","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6631_CR64","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","volume":"25","author":"MFX Gnant","year":"2007","unstructured":"Gnant MFX, Mlineritsch B, Luschin-Ebengreuth G et al (2007) Zoledronic Acid Prevents Cancer Treatment-Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25:820\u2013828","journal-title":"J Clin Oncol"},{"key":"6631_CR65","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","volume":"14","author":"I Fogelman","year":"2003","unstructured":"Fogelman I, Blake GM, Blamey R et al (2003) Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 14:1001\u20131006","journal-title":"Osteoporos Int"},{"key":"6631_CR66","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","volume":"19","author":"CL Shapiro","year":"2001","unstructured":"Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306\u20133311","journal-title":"J Clin Oncol"},{"key":"6631_CR67","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari N, Ghasemi H, Mohammadi L et al (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16:609","journal-title":"J Orthop Surg Res"},{"key":"6631_CR68","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294:238\u2013244","journal-title":"JAMA"},{"key":"6631_CR69","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1210\/jc.2005-0183","volume":"90","author":"SL Greenspan","year":"2005","unstructured":"Greenspan SL, Coates P, Sereika SM et al (2005) Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 90:6410\u20136417","journal-title":"J Clin Endocrinol Metab"},{"key":"6631_CR70","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1056\/NEJM198411153112004","volume":"311","author":"Group TLS, The Leuprolide Study Group","year":"1984","unstructured":"Group TLS, The Leuprolide Study Group (1984) Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer. N Engl J Med 311:1281\u20131286","journal-title":"N Engl J Med"},{"key":"6631_CR71","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s11764-009-0114-1","volume":"4","author":"F Haseen","year":"2010","unstructured":"Haseen F, Murray LJ, Cardwell CR et al (2010) The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis. J Cancer Surviv 4:128\u2013139","journal-title":"J Cancer Surviv"},{"key":"6631_CR72","doi-asserted-by":"publisher","unstructured":"Kim DK, Lee JY, Kim KJ et al (2019) Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis. J Clin Med Res 8. https:\/\/doi.org\/10.3390\/jcm8010113","DOI":"10.3390\/jcm8010113"},{"key":"6631_CR73","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12020-015-0536-7","volume":"50","author":"A-CM Lassemillante","year":"2015","unstructured":"Lassemillante A-CM, Doi SAR, Hooper JD et al (2015) Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy. Endocr 50:344\u2013354","journal-title":"Endocr"},{"key":"6631_CR74","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12020-013-0083-z","volume":"45","author":"A-CM Lassemillante","year":"2014","unstructured":"Lassemillante A-CM, Doi SAR, Hooper JD et al (2014) Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis. Endocr 45:370\u2013381","journal-title":"Endocr"},{"key":"6631_CR75","doi-asserted-by":"publisher","first-page":"652979","DOI":"10.3389\/fphar.2021.652979","volume":"12","author":"CC Wu","year":"2021","unstructured":"Wu CC, Chen PY, Wang SW et al (2021) Risk of Fracture During Androgen Deprivation Therapy Among Patients With Prostate Cancer: A Systematic Review and Meta-Analysis of Cohort Studies. Front Pharmacol 12:652979","journal-title":"Front Pharmacol"},{"key":"6631_CR76","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1464-410X.2012.11758.x","volume":"111","author":"Y-H Shao","year":"2013","unstructured":"Shao Y-H, Moore DF, Shih W et al (2013) Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int 111:745\u2013752","journal-title":"BJU Int"},{"key":"6631_CR77","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154\u2013164","journal-title":"N Engl J Med"},{"key":"6631_CR78","doi-asserted-by":"publisher","first-page":"7897","DOI":"10.1200\/JCO.2004.00.6908","volume":"23","author":"MR Smith","year":"2005","unstructured":"Smith MR, Lee WC, Brandman J et al (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23:7897\u20137903","journal-title":"J Clin Oncol"},{"key":"6631_CR79","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1186\/s12885-015-1843-3","volume":"15","author":"A Wang","year":"2015","unstructured":"Wang A, Obertov\u00e1 Z, Brown C et al (2015) Risk of fracture in men with prostate cancer on androgen deprivation therapy: a population-based cohort study in New Zealand. BMC Cancer 15:837","journal-title":"BMC Cancer"},{"key":"6631_CR80","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","volume":"168","author":"MG Oefelein","year":"2002","unstructured":"Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168:1005\u20131007","journal-title":"J Urol"},{"key":"6631_CR81","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1210\/er.2015-1106","volume":"37","author":"JHD Bassett","year":"2016","unstructured":"Bassett JHD, Duncan Bassett JH, Williams GR (2016) Role of Thyroid Hormones in Skeletal Development and Bone Maintenance. Endocr Rev 37:135\u2013187","journal-title":"Endocr Rev"},{"key":"6631_CR82","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ecl.2018.10.008","volume":"48","author":"B Biondi","year":"2019","unstructured":"Biondi B, Cooper DS (2019) Thyroid Hormone Suppression Therapy. Endocrinol Metab Clin North Am 48:227\u2013237","journal-title":"Endocrinol Metab Clin North Am"},{"key":"6631_CR83","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1001\/jama.2015.5161","volume":"313","author":"MR Blum","year":"2015","unstructured":"Blum MR, Bauer DC, Collet T-H et al (2015) Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA 313:2055\u20132065","journal-title":"JAMA"},{"key":"6631_CR84","doi-asserted-by":"crossref","unstructured":"Ku EJ, Yoo WS, Lee EK, et al (2021) Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab","DOI":"10.1210\/clinem\/dgab539"},{"key":"6631_CR85","doi-asserted-by":"publisher","first-page":"e043007","DOI":"10.1136\/bmjopen-2020-043007","volume":"11","author":"D Kwak","year":"2021","unstructured":"Kwak D, Ha J, Won Y et al (2021) Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMJ Open 11:e043007","journal-title":"BMJ Open"},{"key":"6631_CR86","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s40618-021-01537-0","volume":"44","author":"B\u00c9CA Sousa","year":"2021","unstructured":"Sousa B\u00c9CA, Sousa B\u00c9C, Silva BC et al (2021) Trabecular bone score in women with differentiated thyroid cancer on long-term TSH-suppressive therapy. J Endocrinol Invest 44:2295\u20132305","journal-title":"J Endocrinol Invest"},{"key":"6631_CR87","doi-asserted-by":"publisher","first-page":"45","DOI":"10.11005\/jbm.2019.26.1.45","volume":"26","author":"Y Lee","year":"2019","unstructured":"Lee Y, Yoon B-H, Lee S et al (2019) Risk of Osteoporotic Fractures after Thyroid-stimulating Hormone Suppression Therapy in Patients with Thyroid Cancer. J Bone Metab 26:45\u201350","journal-title":"J Bone Metab"},{"key":"6631_CR88","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/03007995.2017.1378174","volume":"34","author":"S-Y Lin","year":"2018","unstructured":"Lin S-Y, Lin C-L, Chen H-T, Kao C-H (2018) Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study. Curr Med Res Opin 34:805\u2013812","journal-title":"Curr Med Res Opin"},{"key":"6631_CR89","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/jbmr.3407","volume":"33","author":"DW Shin","year":"2018","unstructured":"Shin DW, Suh B, Lim H et al (2018) J-Shaped Association Between Postoperative Levothyroxine Dosage and Fracture Risk in Thyroid Cancer Patients: A Retrospective Cohort Study. J Bone Miner Res 33:1037\u20131043","journal-title":"J Bone Miner Res"},{"key":"6631_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26:1\u2013133","journal-title":"Thyroid"},{"key":"6631_CR91","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"6631_CR92","doi-asserted-by":"publisher","first-page":"470","DOI":"10.5468\/ogs.20012","volume":"63","author":"JE Lee","year":"2020","unstructured":"Lee JE, Park CY, Lee E, Ji YI (2020) Effect of gynecological cancer and its treatment on bone mineral density and the risk of osteoporosis and osteoporotic fracture. Obstet Gynecol Sci 63:470\u2013479","journal-title":"Obstet Gynecol Sci"},{"key":"6631_CR93","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1111\/ajco.12584","volume":"12","author":"SW Lee","year":"2016","unstructured":"Lee SW, Yeo SG, Oh I-H et al (2016) Bone mineral density in women treated for various types of gynecological cancer. Asia Pac J Clin Oncol 12:e398\u2013e404","journal-title":"Asia Pac J Clin Oncol"},{"key":"6631_CR94","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1136\/ijgc-2021-003169","volume":"32","author":"J Sobecki","year":"2022","unstructured":"Sobecki J, Weigman B, Anderson-Carter I et al (2022) Opportunistic osteoporosis screening using routine computed tomography images to identify bone loss in gynecologic cancer survivors. Int J Gynecol Cancer 32:1050\u20131055","journal-title":"Int J Gynecol Cancer"},{"key":"6631_CR95","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/GME.0000000000000692","volume":"23","author":"EA Hibler","year":"2016","unstructured":"Hibler EA, Kauderer J, Greene MH et al (2016) Bone loss after oophorectomy among high-risk women: an NRG oncology\/gynecologic oncology group study. Menopause 23:1228\u20131232","journal-title":"Menopause"},{"key":"6631_CR96","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0378-5122(03)00040-9","volume":"44","author":"DJ Hadjidakis","year":"2003","unstructured":"Hadjidakis DJ, Kokkinakis EP, Sfakianakis ME, Raptis SA (2003) Bone density patterns after normal and premature menopause. Maturitas 44:279\u2013286","journal-title":"Maturitas"},{"key":"6631_CR97","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ijrobp.2020.05.013","volume":"108","author":"N Razavian","year":"2020","unstructured":"Razavian N, Laucis A, Sun Y et al (2020) Radiation-Induced Insufficiency Fractures After Pelvic Irradiation for Gynecologic Malignancies: A Systematic Review. Int J Radiat Oncol*Biol*Phys 108:620\u2013634","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"6631_CR98","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/gme.0b013e318239caeb","volume":"19","author":"KK Vesco","year":"2012","unstructured":"Vesco KK, Marshall LM, Nelson HD et al (2012) Surgical menopause and nonvertebral fracture risk among older US women. Menopause 19:510\u2013516","journal-title":"Menopause"},{"key":"6631_CR99","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/0895-4356(96)00211-9","volume":"49","author":"LJ Melton 3rd","year":"1996","unstructured":"Melton LJ 3rd, Crowson CS, Malkasian GD, O\u2019Fallon WM (1996) Fracture risk following bilateral oophorectomy. J Clin Epidemiol 49:1111\u20131115","journal-title":"J Clin Epidemiol"},{"key":"6631_CR100","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejca.2014.11.022","volume":"51","author":"IE Fakkert","year":"2015","unstructured":"Fakkert IE, Abma EM, Westrik IG et al (2015) Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer. Eur J Cancer 51:400\u2013408","journal-title":"Eur J Cancer"},{"key":"6631_CR101","doi-asserted-by":"crossref","unstructured":"Kumar SK, Rajkumar V, Kyle RA et al (2017) Multiple myeloma. Nature Reviews Disease Primers 3:17046","DOI":"10.1038\/nrdp.2017.46"},{"key":"6631_CR102","doi-asserted-by":"crossref","unstructured":"Roodman GD, David Roodman G (2013) Role of Bone Disease in the Pathogenesis of Multiple Myeloma. Genet Mol Epidemiol Mult Myeloma 97\u2013120","DOI":"10.1007\/978-1-4614-4660-6_6"},{"key":"6631_CR103","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3324\/haematol.2019.230011","volume":"105","author":"S Thorsteinsdottir","year":"2020","unstructured":"Thorsteinsdottir S, Gislason G, Aspelund T et al (2020) Fractures and survival in multiple myeloma: results from a population-based study. Haematol 105:1067\u20131073","journal-title":"Haematol"},{"key":"6631_CR104","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/hon.2303","volume":"35","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Dagan A, Robenshtok E et al (2017) Bone mineral density utilization in patients with newly diagnosed multiple myeloma. Hematol Oncol 35:703\u2013710","journal-title":"Hematol Oncol"},{"key":"6631_CR105","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/10428199809059252","volume":"32","author":"M Dhodapkar","year":"1998","unstructured":"Dhodapkar M, Weinstein R, Tricot G et al (1998) Biologic and Therapeutic Determinants of Bone Mineral Density in Multiple Myeloma. Leuk Lymphoma 32:121\u2013127","journal-title":"Leuk Lymphoma"},{"key":"6631_CR106","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/1097-0142(19951101)76:9<1559::AID-CNCR2820760910>3.0.CO;2-R","volume":"76","author":"X Mariette","year":"1995","unstructured":"Mariette X, Bergot C, Ravaud P et al (1995) Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy. Cancer 76:1559\u20131563","journal-title":"Cancer"},{"key":"6631_CR107","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1359\/JBMR.041131","volume":"20","author":"LJ Melton","year":"2004","unstructured":"Melton LJ, Joseph Melton L, Kyle RA et al (2004) Fracture Risk With Multiple Myeloma: A Population-Based Study. J Bone Miner Res 20:487\u2013493","journal-title":"J Bone Miner Res"},{"key":"6631_CR108","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1359\/jbmr.0301212","volume":"19","author":"LJ Melton","year":"2003","unstructured":"Melton LJ, Joseph Melton L, Vincent Rajkumar S et al (2003) Fracture Risk in Monoclonal Gammopathy of Undetermined Significance. J Bone Miner Res 19:25\u201330","journal-title":"J Bone Miner Res"},{"key":"6631_CR109","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","volume":"134","author":"J Pepe","year":"2006","unstructured":"Pepe J, Petrucci MT, Nofroni I et al (2006) Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol 134:485\u2013490","journal-title":"Br J Haematol"},{"key":"6631_CR110","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/ejh.13633","volume":"107","author":"S R\u00f6gnvaldsson","year":"2021","unstructured":"R\u00f6gnvaldsson S, Aspelund T, Thorsteinsd\u00f3ttir S et al (2021) Untangling fracture risk in monoclonal gammopathy of undetermined significance: A population-based cohort study. Eur J Haematol 107:137\u2013144","journal-title":"Eur J Haematol"},{"key":"6631_CR111","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s00198-018-4669-4","volume":"29","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Body JJ, Brandi ML et al (2018) Bone management in hematologic stem cell transplant recipients. Osteoporos Int 29:2597\u20132610","journal-title":"Osteoporos Int"},{"key":"6631_CR112","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/bmt.2015.329","volume":"51","author":"M Pawlowska","year":"2016","unstructured":"Pawlowska M, Yang Q, Hamata B et al (2016) Early changes in bone mineral density and trabecular bone score following allogeneic stem cell transplant. Bone Marrow Transplant 51:738\u2013740","journal-title":"Bone Marrow Transplant"},{"key":"6631_CR113","doi-asserted-by":"publisher","first-page":"100361","DOI":"10.1016\/j.jbo.2021.100361","volume":"28","author":"DL Kendler","year":"2021","unstructured":"Kendler DL, Body JJ, Brandi ML et al (2021) Osteoporosis management in hematologic stem cell transplant recipients: Executive summary. J Bone Oncol 28:100361","journal-title":"J Bone Oncol"},{"key":"6631_CR114","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3803\/EnM.2021.1248","volume":"36","author":"E Jang","year":"2021","unstructured":"Jang E, Ha J, Baek K-H, Kang MI (2021) Changes in Serum Dickkopf-1, RANK Ligand, Osteoprotegerin, and Bone Mineral Density after Allogeneic Hematopoietic Stem Cell Transplantation Treatment. Endocrinol Metab (Seoul) 36:1211\u20131218","journal-title":"Endocrinol Metab (Seoul)"},{"key":"6631_CR115","doi-asserted-by":"publisher","first-page":"105373","DOI":"10.1016\/j.jbspin.2022.105373","volume":"89","author":"D Leguy","year":"2022","unstructured":"Leguy D, Magro L, Pierache A et al (2022) Changes in bone mineral density after allogenic stem cell transplantation. Joint Bone Spine 89:105373","journal-title":"Joint Bone Spine"},{"key":"6631_CR116","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/sj.bmt.1704535","volume":"34","author":"W-Y Lee","year":"2004","unstructured":"Lee W-Y, Baek K-H, Rhee E-J et al (2004) Impact of circulating bone-resorbing cytokines on the subsequent bone loss following bone marrow transplantation. Bone Marrow Transplant 34:89\u201394","journal-title":"Bone Marrow Transplant"},{"key":"6631_CR117","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1046\/j.1365-2141.2003.04303.x","volume":"121","author":"MK Gandhi","year":"2003","unstructured":"Gandhi MK, Lekamwasam S, Inman I et al (2003) Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. Br J Haematol 121:462\u2013468","journal-title":"Br J Haematol"},{"key":"6631_CR118","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2014.57.8195","volume":"33","author":"XN Pundole","year":"2015","unstructured":"Pundole XN, Barbo AG, Lin H et al (2015) Increased incidence of fractures in recipients of hematopoietic stem-cell transplantation. J Clin Oncol 33:1364\u20131370","journal-title":"J Clin Oncol"},{"key":"6631_CR119","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/bmt.2013.64","volume":"48","author":"T Schechter","year":"2013","unstructured":"Schechter T, Pole JD, Darmawikarta D et al (2013) Late mortality after hematopoietic SCT for a childhood malignancy. Bone Marrow Transplant 48:1291\u20131295","journal-title":"Bone Marrow Transplant"},{"key":"6631_CR120","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-019-0484-6","volume":"54","author":"A Baumgartner","year":"2019","unstructured":"Baumgartner A, Moesch M, Zumsteg M et al (2019) Predictors of impaired bone health in long-term survivors after allogeneic stem cell transplantation. Bone Marrow Transplant 54:1651\u20131661","journal-title":"Bone Marrow Transplant"},{"key":"6631_CR121","doi-asserted-by":"publisher","first-page":"34811","DOI":"10.18632\/oncotarget.16746","volume":"8","author":"J-N Lin","year":"2017","unstructured":"Lin J-N, Chen H-J, Yang C-H et al (2017) Risk of osteoporosis and pathologic fractures in cancer patients who underwent hematopoietic stem cell transplantation: a nationwide retrospective cohort study. Oncotarget 8:34811\u201334819","journal-title":"Oncotarget"},{"key":"6631_CR122","doi-asserted-by":"publisher","first-page":"527","DOI":"10.5144\/0256-4947.1994.527","volume":"14","author":"NN Ghannam","year":"1994","unstructured":"Ghannam NN (1994) Assessment of Fracture Risk and its Application to Screening for Postmenopausal OsteoporosisAssessment of Fracture Risk and its Application to Screening for Postmenopausal Osteoporosis. WHO Technical Report Series 843. World Health Organization, Geneva. Ann Saudi Med 14:527\u2013527","journal-title":"Ann Saudi Med"},{"key":"6631_CR123","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11657-018-0510-0","volume":"13","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Johansson H, Harvey NC, McCloskey EV (2018) A brief history of FRAX. Arch Osteoporos 13:118","journal-title":"Arch Osteoporos"},{"key":"6631_CR124","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00198-015-3295-7","volume":"27","author":"NC Harvey","year":"2016","unstructured":"Harvey NC, Johansson H, Od\u00e9n A et al (2016) FRAX predicts incident falls in elderly men: findings from MrOs Sweden. Osteoporos Int 27:267\u2013274","journal-title":"Osteoporos Int"},{"key":"6631_CR125","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jbmr.3331","volume":"33","author":"NC Harvey","year":"2018","unstructured":"Harvey NC, Od\u00e9n A, Orwoll E et al (2018) Falls Predict Fractures Independently of FRAX Probability: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. J Bone Miner Res 33:510\u2013516","journal-title":"J Bone Miner Res"},{"key":"6631_CR126","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00198-012-2051-5","volume":"24","author":"WD Leslie","year":"2013","unstructured":"Leslie WD, Lix LM, Wu X et al (2013) Competing mortality and fracture risk assessment. Osteoporos Int 24:681\u2013688","journal-title":"Osteoporos Int"},{"key":"6631_CR127","unstructured":"Ye C, Leslie WD, Al-Azazi S, Yan L, Lix LM, Czaykowski P, McCloskey EV, Johansson H, Harvey NC, Kanis JA, Singh H 2022 FRAX Underestimates Major Osteoporotic Fracture Risk in Cancer Survivors: A Registry-Based Cohort Study. ASBMR Abstract Book. Available at https:\/\/wwwasbmr.org\/ASBMR-abstracts. Accessed September 16, 2022"},{"key":"6631_CR128","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00198-010-1524-7","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2011) Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 22:809\u2013816","journal-title":"Osteoporos Int"},{"key":"6631_CR129","doi-asserted-by":"publisher","first-page":"e3427","DOI":"10.1136\/bmj.e3427","volume":"344","author":"J Hippisley-Cox","year":"2012","unstructured":"Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 344:e3427","journal-title":"BMJ"},{"issue":"Suppl 3","key":"6631_CR130","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","volume":"11","author":"JR Gralow","year":"2013","unstructured":"Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar R, Litsas G, McKay R, Podoloff DA, Srinivas S, Van Poznak CH (2013) NCCN Task Force Report: Bone Health In Cancer Care. J Natl Compr Canc Netw 11(Suppl 3):S1-50","journal-title":"J Natl Compr Canc Netw"},{"key":"6631_CR131","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1007\/s00198-013-2530-3","volume":"24","author":"R Rizzoli","year":"2013","unstructured":"Rizzoli R, for the International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer-Induced Bone Disease, Body J-J et al (2013) Cancer-associated bone disease. Osteoporos Int 24:2929\u20132953","journal-title":"Osteoporos Int"},{"key":"6631_CR132","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2104162","volume":"385","author":"M Gnant","year":"2021","unstructured":"Gnant M, Fitzal F, Rinnerthaler G et al (2021) Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. N Engl J Med 385:395\u2013405","journal-title":"N Engl J Med"},{"key":"6631_CR133","doi-asserted-by":"publisher","first-page":"e10440","DOI":"10.1002\/jbm4.10440","volume":"5","author":"S Monteverdi","year":"2021","unstructured":"Monteverdi S, Pedersini R, Gallo F et al (2021) The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy. JBMR Plus 5:e10440","journal-title":"JBMR Plus"},{"key":"6631_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro MS, Body J-J et al (2017) Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. J Bone Oncol 7:1\u201312","journal-title":"J Bone Oncol"},{"key":"6631_CR135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/4636028","volume":"2018","author":"RS Prawiradilaga","year":"2018","unstructured":"Prawiradilaga RS, Gunmalm V, Lund-Jacobsen T et al (2018) FRAX Calculated without BMD Resulting in a Higher Fracture Risk Than That Calculated with BMD in Women with Early Breast Cancer. J Osteoporos 2018:1\u20136","journal-title":"J Osteoporos"},{"key":"6631_CR136","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jbo.2016.10.004","volume":"7","author":"V Mariotti","year":"2017","unstructured":"Mariotti V, Page DB, Davydov O et al (2017) Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. J Bone Oncol 7:32\u201337","journal-title":"J Bone Oncol"},{"key":"6631_CR137","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s40618-014-0125-2","volume":"37","author":"M Pedrazzoni","year":"2014","unstructured":"Pedrazzoni M, Casola A, Verzicco I et al (2014) Longitudinal changes of trabecular bone score after estrogen deprivation: effect of menopause and aromatase inhibition. J Endocrinol Invest 37:871\u2013874","journal-title":"J Endocrinol Invest"},{"key":"6631_CR138","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jocd.2013.03.003","volume":"17","author":"M Kalder","year":"2014","unstructured":"Kalder M, Hans D, Kyvernitakis I et al (2014) Effects of Exemestane and Tamoxifen Treatment on Bone Texture Analysis Assessed by TBS in Comparison With Bone Mineral Density Assessed by DXA in Women With Breast Cancer. J Clin Densitom 17:66\u201371","journal-title":"J Clin Densitom"},{"key":"6631_CR139","doi-asserted-by":"publisher","first-page":"e0240084","DOI":"10.1371\/journal.pone.0240084","volume":"15","author":"SH Park","year":"2020","unstructured":"Park SH, Jeong YM, Lee HY et al (2020) Opportunistic use of chest CT for screening osteoporosis and predicting the risk of incidental fracture in breast cancer patients: A retrospective longitudinal study. PLoS One 15:e0240084","journal-title":"PLoS One"},{"key":"6631_CR140","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jbspin.2019.07.005","volume":"86","author":"B Bouvard","year":"2019","unstructured":"Bouvard B, Confavreux CB, Briot K et al (2019) French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies. Joint Bone Spine 86:542\u2013553","journal-title":"Joint Bone Spine"},{"key":"6631_CR141","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body J-J et al (2020) Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 31:1650\u20131663","journal-title":"Ann Oncol"},{"key":"6631_CR142","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/GME.0000000000000515","volume":"23","author":"P Villa","year":"2016","unstructured":"Villa P, Lassandro AP, Amar ID et al (2016) Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer. Menopause 23:33\u201339","journal-title":"Menopause"},{"key":"6631_CR143","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/annonc\/mdr356","volume":"23","author":"B Bouvard","year":"2012","unstructured":"Bouvard B, Hopp\u00e9 E, Souli\u00e9 P et al (2012) High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy. Ann Oncol 23:1151\u20131156","journal-title":"Ann Oncol"},{"key":"6631_CR144","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.bone.2017.01.013","volume":"97","author":"R Pedersini","year":"2017","unstructured":"Pedersini R, Monteverdi S, Mazziotti G et al (2017) Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. Bone 97:147\u2013152","journal-title":"Bone"},{"key":"6631_CR145","doi-asserted-by":"publisher","first-page":"100355","DOI":"10.1016\/j.jbo.2021.100355","volume":"28","author":"K Waqas","year":"2021","unstructured":"Waqas K, Ferreira JL, Tsourdi E et al (2021) Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. J Bone Oncol 28:100355","journal-title":"J Bone Oncol"},{"key":"6631_CR146","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.bone.2008.05.003","volume":"43","author":"HG Ahlborg","year":"2008","unstructured":"Ahlborg HG, Nguyen ND, Center JR et al (2008) Incidence and risk factors for low trauma fractures in men with prostate cancer. Bone 43:556\u2013560","journal-title":"Bone"},{"key":"6631_CR147","first-page":"9517","volume":"27","author":"D Lin","year":"2009","unstructured":"Lin D, Smith MR, Morton RA, Steiner MS (2009) Use of age and BMD to predict fracture risk in men on androgen deprivation therapy. J Clin Orthod 27:9517\u20139517","journal-title":"J Clin Orthod"},{"key":"6631_CR148","unstructured":"Ye C, Morin SN, Lix L, McCloskey EV, Johansson H, Harvey NC, Kanis JA, Leslie WD (2022) Performance of FRAX in Men with Prostate Cancer: A Registry-Based Cohort Study. ASBMR Abstract Book. Available at https:\/\/wwwasbmr.org\/ASBMR-abstracts. Accessed September 16, 2022"},{"key":"6631_CR149","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11914-014-0242-z","volume":"12","author":"N Binkley","year":"2014","unstructured":"Binkley N, Adler R, Bilezikian JP (2014) Osteoporosis Diagnosis in Men: The T-Score Controversy Revisited. Curr Osteoporos Rep 12:403\u2013409","journal-title":"Curr Osteoporos Rep"},{"key":"6631_CR150","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.jbo.2020.100311","volume":"25","author":"JE Brown","year":"2020","unstructured":"Brown JE, Handforth C, Compston JE et al (2020) Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. J Bone Oncol 25:100311","journal-title":"J Bone Oncol"},{"key":"6631_CR151","doi-asserted-by":"publisher","first-page":"245","DOI":"10.5152\/tud.2019.11736","volume":"45","author":"A Sharma","year":"2019","unstructured":"Sharma A, Sinha RJ, Singh V et al (2019) Implications of the Fracture Risk Assessment Algorithm for the assessment and improvement of bone health in patients with prostate cancer: A comprehensive review. Turk J Urol 45:245\u2013253","journal-title":"Turk J Urol"},{"key":"6631_CR152","unstructured":"National Institute for Health and Clinical Excellence (NICE). Prostate cancer: diagnosis and management. Clinical guideline 131. London, UK: 2019. Available from: https:\/\/www.nice.org.uk\/guidance\/ng131"},{"key":"6631_CR153","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1200\/JCO.19.03148","volume":"38","author":"PJ Saylor","year":"2020","unstructured":"Saylor PJ, Bryan Rumble R, Tagawa S et al (2020) Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. J Clin Oncol 38:1736\u20131743","journal-title":"J Clin Oncol"},{"key":"6631_CR154","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Version 2.2020. Page 46"},{"key":"6631_CR155","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 71:618\u2013629","journal-title":"Eur Urol"},{"key":"6631_CR156","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jocd.2016.04.011","volume":"19","author":"AM McDonald","year":"2016","unstructured":"McDonald AM, Jones JA, Cardan RA et al (2016) Combining Computed Tomography-Based Bone Density Assessment with FRAX Screening in Men with Prostate Cancer. J Clin Densitom 19:430\u2013435","journal-title":"J Clin Densitom"},{"key":"6631_CR157","first-page":"350","volume":"67","author":"L Vera","year":"2016","unstructured":"Vera L, Gay S, Campomenosi C et al (2016) Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy. Endokrynol Pol 67:350\u2013358","journal-title":"Endokrynol Pol"},{"key":"6631_CR158","doi-asserted-by":"publisher","unstructured":"Chung CW, Choi HS, Kong SH et al (2021) Measurements of Bone Health after Thyroid-Stimulating Suppression Therapy in Postmenopausal Women with Differentiated Thyroid Carcinoma: Bone Mineral Density versus the Trabecular Bone Score. J Clin Med Res 10.\u00a0https:\/\/doi.org\/10.3390\/jcm10091964","DOI":"10.3390\/jcm10091964"},{"key":"6631_CR159","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/cen.14698","volume":"97","author":"H Park","year":"2022","unstructured":"Park H, Park J, Yoo H et al (2022) Bone-density testing interval and transition to osteoporosis in differentiated thyroid carcinoma patients on TSH suppression therapy. Clin Endocrinol 97:130\u2013136","journal-title":"Clin Endocrinol"},{"key":"6631_CR160","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ygyno.2020.11.028","volume":"160","author":"JN Sobecki","year":"2021","unstructured":"Sobecki JN, Rice LW, Hartenbach EM (2021) Bone health and osteoporosis screening in gynecologic cancer survivors. Gynecol Oncol 160:619\u2013624","journal-title":"Gynecol Oncol"},{"key":"6631_CR161","doi-asserted-by":"publisher","first-page":"322","DOI":"10.5606\/tftrd.2021.5918","volume":"67","author":"A Utkan Karasu","year":"2021","unstructured":"Utkan Karasu A, Karasu Y, \u00d6zak\u015fit MG et al (2021) Comparison of osteoporotic fracture risk in surgical and natural menopausal patients. Turk J Phys Med Rehabil 67:322\u2013327","journal-title":"Turk J Phys Med Rehabil"},{"key":"6631_CR162","doi-asserted-by":"publisher","first-page":"813","DOI":"10.6004\/jnccn.2014.0196","volume":"12","author":"A Farooki","year":"2014","unstructured":"Farooki A (2014) NCCN Bone Health Task Force: Key Recommendations. J Natl Compr Canc Netw 12:813\u2013816","journal-title":"J Natl Compr Canc Netw"},{"key":"6631_CR163","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.01696","volume":"37","author":"CL Shapiro","year":"2019","unstructured":"Shapiro CL, Van Poznak C, Lacchetti C et al (2019) Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. J Clin Oncol 37:2916\u20132946","journal-title":"J Clin Oncol"},{"key":"6631_CR164","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.ygyno.2019.06.017","volume":"155","author":"L-M Chen","year":"2019","unstructured":"Chen L-M, Blank SV, Burton E et al (2019) Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review. Gynecol Oncol 155:508\u2013514","journal-title":"Gynecol Oncol"},{"key":"6631_CR165","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/CORR.0000000000001303","volume":"479","author":"GR Toci","year":"2021","unstructured":"Toci GR, Bressner JA, Morris CD et al (2021) Can a Novel Scoring System Improve on the Mirels Score in Predicting the Fracture Risk in Patients with Multiple Myeloma? Clin Orthop Relat Res 479:521\u2013530","journal-title":"Clin Orthop Relat Res"},{"key":"6631_CR166","doi-asserted-by":"crossref","unstructured":"Hansford BG, Silbermann R (2018) Advanced Imaging of Multiple Myeloma Bone Disease. Front Endocrinol 9","DOI":"10.3389\/fendo.2018.00436"},{"key":"6631_CR167","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s42058-020-00038-y","volume":"3","author":"W Huang","year":"2020","unstructured":"Huang W, Dong H, Ji X, Xia S (2020) Advanced imaging in evaluation of bone disease of multiple myeloma. Chin J Acad Radiol 3:76\u201383","journal-title":"Chin J Acad Radiol"},{"key":"6631_CR168","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s00277-002-0532-x","volume":"81","author":"A S","year":"2002","unstructured":"S A, W H-J, S C et al (2002) Vertebral fractures in multiple myeloma: first results of assessment of fracture risk using dynamic contrast-enhanced magnetic resonance imaging. Ann Hematol 81:517\u2013521","journal-title":"Ann Hematol"},{"key":"6631_CR169","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.bone.2018.09.013","volume":"121","author":"S Atrash","year":"2019","unstructured":"Atrash S, Dua I, Buros AF et al (2019) FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients. Bone 121:134\u2013138","journal-title":"Bone"},{"key":"6631_CR170","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11657-018-0453-5","volume":"13","author":"X Pundole","year":"2018","unstructured":"Pundole X, Murphy WA, Ebede CC et al (2018) Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. Arch Osteoporos 13:38","journal-title":"Arch Osteoporos"},{"key":"6631_CR171","unstructured":"Rizzo W, Lee T (n.d.) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European \u2026. Biol Blood Marrow Transplant"},{"key":"6631_CR172","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1432-2277.2011.01264.x","volume":"24","author":"AH Hautmann","year":"2011","unstructured":"Hautmann AH, Elad S, Lawitschka A et al (2011) Metabolic bone diseases in patients after allogeneic hematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Transpl Int 24:867\u2013879","journal-title":"Transpl Int"},{"key":"6631_CR173","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/bmt.2010.198","volume":"46","author":"BL McClune","year":"2011","unstructured":"McClune BL, Polgreen LE, Burmeister LA et al (2011) Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipients. Bone Marrow Transplant 46:1\u20139","journal-title":"Bone Marrow Transplant"},{"key":"6631_CR174","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ctrv.2016.10.004","volume":"51","author":"JJ Body","year":"2016","unstructured":"Body JJ, Terpos E, Tombal B et al (2016) Bone health in the elderly cancer patient: A SIOG position paper. Cancer Treat Rev 51:46\u201353","journal-title":"Cancer Treat Rev"},{"key":"6631_CR175","doi-asserted-by":"crossref","unstructured":"Alibhai SMH, Zukotynski K, Walker-Dilks C et al (2017) Cancer Care Ontario Genitourinary Cancer Disease Site Group. Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline. Clin Oncol 29:348\u2013355","DOI":"10.1016\/j.clon.2017.01.007"},{"key":"6631_CR176","unstructured":"Mottet N, Bellmunt J, Briers E, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. 2016. Available from: https:\/\/uroweb.org\/wp-content\/uploads\/EAU-Guidelines-Prostate-Cancer-2016.pdf"},{"issue":"Suppl 4","key":"6631_CR177","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdy001","volume":"29","author":"I Ray-Coquard","year":"2018","unstructured":"Ray-Coquard I, Morice P, Lorusso D et al (2018) Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):iv1\u2013iv18","journal-title":"Ann Oncol"},{"key":"6631_CR178","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S1470-2045(20)30559-3","volume":"22","author":"E Terpos","year":"2021","unstructured":"Terpos E, Zamagni E, Lentzsch S et al (2021) Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncol 22:e119\u2013e130","journal-title":"Lancet Oncol"},{"key":"6631_CR179","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JOP.17.00013","volume":"14","author":"K Anderson","year":"2018","unstructured":"Anderson K, Ismaila N, Kyle RA (2018) Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J Oncol Pract 14:266\u2013269","journal-title":"J Oncol Pract"},{"key":"6631_CR180","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1200\/JCO.2010.28.2095","volume":"28","author":"RT Chlebowski","year":"2010","unstructured":"Chlebowski RT, Chen Z, Cauley JA et al (2010) Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582\u20133590","journal-title":"J Clin Oncol"},{"key":"6631_CR181","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/sj.bjc.6605555","volume":"102","author":"PA Newcomb","year":"2010","unstructured":"Newcomb PA, Trentham-Dietz A, Hampton JM (2010) Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer 102:799\u2013802","journal-title":"Br J Cancer"},{"key":"6631_CR182","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1200\/JCO.2010.28.1113","volume":"28","author":"G Rennert","year":"2010","unstructured":"Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577\u20133581","journal-title":"J Clin Oncol"},{"key":"6631_CR183","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","volume":"11","author":"R Aft","year":"2010","unstructured":"Aft R, Naughton M, Trinkaus K et al (2010) Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 11:421\u2013428","journal-title":"Lancet Oncol"},{"key":"6631_CR184","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/cncr.25529","volume":"117","author":"R Coleman","year":"2011","unstructured":"Coleman R, Cook R, Hirsh V et al (2011) Zoledronic acid use in cancer patients: more than just supportive care? Cancer 117:11\u201323","journal-title":"Cancer"},{"key":"6631_CR185","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/sj.bjc.6603661","volume":"96","author":"TC Ha","year":"2007","unstructured":"Ha TC, Li H (2007) Meta-analysis of clodronate and breast cancer survival. Br J Cancer 96:1796\u20131801","journal-title":"Br J Cancer"},{"key":"6631_CR186","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","volume":"21","author":"H Eidtmann","year":"2010","unstructured":"Eidtmann H, de Boer R, Bundred N et al (2010) Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21:2188\u20132194","journal-title":"Ann Oncol"},{"key":"6631_CR187","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B, Schippinger W et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679\u2013691","journal-title":"N Engl J Med"},{"key":"6631_CR188","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386:1353\u20131361","journal-title":"Lancet"},{"key":"6631_CR189","first-page":"1","volume":"50","author":"S-M Jeon","year":"2018","unstructured":"Jeon S-M, Shin E-A (2018) Exploring vitamin D metabolism and function in cancer. Exp Mol Med 50:1\u201314","journal-title":"Exp Mol Med"},{"key":"6631_CR190","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1002\/cam4.4013","volume":"10","author":"JE van Atteveld","year":"2021","unstructured":"van Atteveld JE, Verhagen IE, van den Heuvel-Eibrink MM et al (2021) Vitamin D supplementation for children with cancer: A systematic review and consensus recommendations. Cancer Med 10:4177\u20134194","journal-title":"Cancer Med"},{"key":"6631_CR191","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/nure.12047","volume":"71","author":"L Teleni","year":"2013","unstructured":"Teleni L, Baker J, Koczwara B et al (2013) Clinical outcomes of vitamin D deficiency and supplementation in cancer patients. Nutr Rev 71:611\u2013621","journal-title":"Nutr Rev"},{"key":"6631_CR192","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1809944","volume":"380","author":"JE Manson","year":"2019","unstructured":"Manson JE, Cook NR, Lee I-M et al (2019) Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med 380:33\u201344","journal-title":"N Engl J Med"},{"key":"6631_CR193","doi-asserted-by":"publisher","first-page":"e2025850","DOI":"10.1001\/jamanetworkopen.2020.25850","volume":"3","author":"PD Chandler","year":"2020","unstructured":"Chandler PD, Chen WY, Ajala ON et al (2020) Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial. JAMA Netw Open 3:e2025850","journal-title":"JAMA Netw Open"},{"key":"6631_CR194","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1891\/0739-6686.31.327","volume":"31","author":"MT Knobf","year":"2013","unstructured":"Knobf MT, Winters-Stone K (2013) Exercise and cancer. Annu Rev Nurs Res 31:327\u2013365","journal-title":"Annu Rev Nurs Res"},{"key":"6631_CR195","doi-asserted-by":"publisher","first-page":"R371","DOI":"10.1530\/ERC-14-0172","volume":"21","author":"AS Cheung","year":"2014","unstructured":"Cheung AS, Zajac JD, Grossmann M (2014) Muscle and bone effects of androgen deprivation therapy: current and emerging therapies. Endocr Relat Cancer 21:R371\u2013R394","journal-title":"Endocr Relat Cancer"},{"key":"6631_CR196","doi-asserted-by":"publisher","first-page":"E1967","DOI":"10.1210\/jc.2014-1271","volume":"99","author":"D Padhi","year":"2014","unstructured":"Padhi D, Higano CS, Shore ND et al (2014) Pharmacological Inhibition of Myostatin and Changes in Lean Body Mass and Lower Extremity Muscle Size in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. J Clin Endocrinol Metab 99:E1967\u2013E1975","journal-title":"J Clin Endocrinol Metab"},{"key":"6631_CR197","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1210\/en.2005-0572","volume":"146","author":"W Gao","year":"2005","unstructured":"Gao W, Reiser PJ, Coss CC et al (2005) Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinol 146:4887\u20134897","journal-title":"Endocrinol"},{"key":"6631_CR198","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejphar.2013.10.042","volume":"720","author":"K Akita","year":"2013","unstructured":"Akita K, Harada K, Ichihara J et al (2013) A novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate. Eur J Pharmacol 720:107\u2013114","journal-title":"Eur J Pharmacol"},{"key":"6631_CR199","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s12603-013-0335-x","volume":"17","author":"DA Papanicolaou","year":"2013","unstructured":"Papanicolaou DA, Ather SN, Zhu H et al (2013) A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. J Nutr Health Aging 17:533\u2013543","journal-title":"J Nutr Health Aging"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06631-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06631-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06631-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T05:34:06Z","timestamp":1676093646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06631-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":199,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["6631"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06631-4","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"assertion":[{"value":"20 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}